The stand-alone Ayurveda treatment for the management of COVID-associated mucormycosis (CAM): a case report
-
By
-
Rajnikant Patel
-
Skanthesh Lakshmanan
-
Vinayak Padikkal
-
Keyur Mandaliya
-
June 5, 2026
-
Clinical Scorecard: Ayurveda-Based Management of COVID-Related Mucormycosis: A Case Study
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Individuals with recent COVID-19 infection, particularly those with diabetes or immune compromise, managed with Ayurveda. |
| Care Setting | |
Key Highlights
- Case of a 60-year-old male with COVID-associated mucormycosis managed solely with Ayurveda.
- Diagnostic confirmation through potassium hydroxide testing, histopathology, and fungal culture.
- Patient showed progressive symptomatic improvement with no adverse events during treatment.
- Three-year follow-up indicated no clinical recurrence and normal laboratory parameters.
Guideline-Based Recommendations
Diagnosis
Management
- Consider Ayurveda-based interventions as an alternative approach, if supported by further evidence.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with COVID-19 and subsequent symptoms indicative of mucormycosis.
Ayurvedic management was administered over 15 days and continued for 90 days.
Clinical Best Practices
Related Resources & Content
